Results 211 to 220 of about 506,875 (293)
Advances in Epicardial Access for Ventricular Tachycardia Ablation: From Historical Techniques to Carbon Dioxide Insufflation. [PDF]
Higuchi K +3 more
europepmc +1 more source
Electrocardiogram Characteristics and Outcomes in an Adult Congenital Heart Disease Population
The electrocardiogram (ECG) is a low‐cost, readily available test that can detect dysrhythmia, chamber enlargement, and ischemia in heart disease patients. ECG features and changes over time are linked to adverse cardiac events and mortality in congenital heart disease populations. Further research is needed to develop ECG‐based risk models.
Seyedeh Somayyeh Mousavi +6 more
wiley +1 more source
The VISTA Scores: Development and Internal Validation of Novel Clinical Models for Predicting Recurrence and Mortality After Ventricular Tachycardia Ablation. [PDF]
Stanciulescu L, Dorobantu M.
europepmc +1 more source
Postoperative atrial fibrillation is a common complication following coronary artery bypass grafting and may lead to prolonged hospital stays and increased risk of stroke‐related mortality and morbidity. This study found that lower preoperative left atrial strain and strain rate are effective predictors for POAF in low‐risk patients undergoing CABG ...
Leila Bigdelu +5 more
wiley +1 more source
Feasibility of functional substrate mapping with a novel lattice-tip catheter: Implications for ventricular tachycardia ablation. [PDF]
Letsas KP +8 more
europepmc +1 more source
Lower rates of sudden cardiac arrest and major adverse cardiovascular events in NIDCM patients. Higher rates of in‐hospital mortality, stroke, and heart failure‐related admissions in NIDCM patients. ABSTRACT Background Ventricular tachycardia (VT) is a major cause of morbidity and mortality in patients with structural heart disease, yet real‐world ...
Medhat Chowdhury +9 more
wiley +1 more source
The Role of Imaging in Ventricular Tachycardia Ablation. [PDF]
Notarstefano P +8 more
europepmc +1 more source
Summary Chronic lymphocytic leukaemia (CLL) primarily affects elderly patients with comorbidities, yet real‐world data on acalabrutinib, a second‐generation Bruton's Tyrosine Kinase (BTK) inhibitor, remain limited outside clinical trials, particularly in Italy.
Andrea Duminuco +21 more
wiley +1 more source

